- Home
- SNDX
as 11-15-2024 4:00pm EST
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.6B | IPO Year: | 2016 |
| Target Price: | $36.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.81 - $25.34 | Next Earning Date: | 11-05-2024 |
| Revenue: | $16,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 219.92% |
Latest Syndax Pharmaceuticals Inc. News
SNDX Breaking Stock News: Dive into SNDX Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Zacks
3 days ago
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Pharmaceutical Technology
4 days ago
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
TipRanks
4 days ago
Syndax’s revumenib meets primary results in AML trial
Benzinga
5 days ago
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
PR Newswire
5 days ago
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Simply Wall St.
9 days ago
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
Thomson Reuters StreetEvents
10 days ago
Q3 2024 Royalty Pharma PLC Earnings Call
Compare SNDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.